Prostate Cancer

Description

"This book admirably covers prostate cancer. It is written in an easily digestible manner for non-experts and emphasizes the importance of a team approach to treatment of patients with this disease."--Doody's Reviews

With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice.

The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer's impact on the quality of life. A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study.

Key Features:

Delineates a practical, concise approach to multidisciplinary management of prostate cancer
Provides a wide range of perspectives and expertise
Written and edited by an international, multidisciplinary team of prostate cancer specialists
Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life
Includes discussion of important emerging topics such as gene profiling and targeted therapies and comparative effectiveness data

"

Contents

"; ;

Contributors

;

Series Foreword

;

Preface

;

Acknowledgments

;

I.

;

Epidemiology, Screening, and Diagnosis

;

1 Introduction: The Multidisciplinary Approach to Prostate Cancer

;

Leonard G. Gomella

;

2.1 Epidemiology of Prostate Cancer

;

Kathryn M. Wilson

;

Lorelei A. Mucci

;

2.2 Diet and Prostate Cancer

;

James R. Marshall

;

2.3 Epidemiology: Obesity as a Risk Factor

;

Emma H. Allott

;

Stephen J. Freedland

;

3.1.1 Screening and Diagnosis: The Pros of PSA Screening

;

Janine L. Oliver

;

Gurdarshan S. Sandhu

;

Gerald L. Andriole

;

Robert L. Grubb III

;

3.1.2 The Argument Against Prostate Cancer Screening

;

Otis W. Brawley

;

3.1.3 How Do We Improve PSA Accuracy?

;

Toru Sugihara

;

Michael W. Kattan

;

3.2 Screening and Diagnosis: An Update on the ISUP-Modified Gleason Score and Its Controversies

;

Ibrahim Kulac

;

Angelo M. DeMarzo

;

3.3 Evaluation of Distant Disease: The Utility of Nuclear Imaging

;

Dima Raskolnikov

;

Baris Turkbey

;

Liza Lindenberg

;

Peter L. Choyke

;

Peter A. Pinto

;

4 Current Approaches to Prostate Cancer Staging and Risk Stratification: In the Midst of a Paradigm Shift

;

Chad A. Reichard

;

Eric A. Klein

;

5.1 Novel Molecular and Genotype Profiling in Prostate Cancer: The Future of Screening, Diagnosis, and Staging

;

Heesun Shin

;

Ismael A. Vergara

;

Anirban P. Mitra

;

Timothy J. Triche

;

Elai Davicioni

;

5.2 Genomics and Risk Assessment

;

Hao G. Nguyen

;

Matthew R. Cooperberg

;

Peter R. Carroll

;

5.3 Future Direction: Novel Urine and Serum Markers

;

Waleed A. Hassen

;

5.4 Morphometric and Systems Pathology: The Future of Screening, Diagnosis, and Staging

;

Michael J. Donovan

;

Faisal M. Khan
Richard Scott

;

Gerardo Fernandez

;

Carlos Cordon-Cardo

;

5.5.1 PET: The Future of Screening, Diagnosis, and Staging for Prostate Cancer

;

Mathew L. Thakur

;

Edouard J. Trabulsi

;

Sung M. Kim

;

Charles M. Intenzo

;

Leonard G. Gomella

;

5.5.2 DCE MRI and MR Spectroscopy: The Future of Screening, Diagnosis, and Staging

;

Victor Sai

;

Antonio C. Westphalen

;

5.5.3 Future Direction: Contrast Ultrasound 109

;

Sanjay Kasturi

;

Edouard J. Trabulsi

;

Ethan J. Halpern

;

6 Counseling Patients With Clinically Localized, High-Risk Prostate Cancer

;

Jonathan L. Silberstein

;

James A. Eastham

;

II.

;

Treatment for Low-Risk, Localized Disease

;

7 Active Surveillance for Prostate Cancer: An Overview

;

Laurence Klotz

;

8 Treatment of Low-Risk, Localized Prostate Cancer: A Holistic Approach With Diet

;

Jillian Scambia

;

Annie DarvesñBornoz

;

Aaron Katz

;

9.1 Traditional Radical Prostatectomy

;

Zachary L. Smith

;

Thomas J. Guzzo

;

9.2 Laparoscopic Radical Prostatectomy: Techniques and Complications

;

Fernando Pablo Secin

;

Karim Touijer

;

9.3 Robotic Radical Prostatectomy: The Thomas Jefferson University Experience

;

Costas D. Lallas

;

Edouard J. Trabulsi

;

9.4 Surgical Training, Digital Capture, Virtual Reality, and the Future of Radical Prostatectomy

;

Costas D. Lallas

;

10.1.1 External Beam Radiation Therapy: Conventional Fractionation

;

David E. Greene

;

Richard K. Valicenti

;

10.1.2 Hypofractionated Radiation Therapy for Localized Prostate Cancer

;

Nicholas G. Zaorsky

;

Robert B. Den

;

10.1.3 Stereotactic Body Radiation Therapy for Localized Prostate Cancer

;

Nicholas G. Zaorsky

;

Robert B. Den

;

10.1.4 Treatment of Low-Risk, Localized Prostate Cancer: Use of Proton Therapy

;

Phillip J. Gray

;

Ayal A. Aizer

;

Jason A. Efstathiou

;

10.2 Treatment of Low-Risk, Localized Prostate Cancer: Brachytherapy

;

Peter Grimm

;

11.1 Treatment of Low-Risk, Localized Prostate Cancer: General Principles of Ablative and Focal Therapies

;

Joshua A. Cohn

;

Aytekin Oto

;

Scott E. Eggener

;

11.2 Hyperthermia for Prostate Cancer

;

Mark Hurwitz

;

11.3 Ablative Techniques: Vascular Targeted Photodynamic Therapy

;

Ashley G. Winter

;

Jonathan A. Coleman

;

11.4 Laser Ablative Techniques for Prostate Cancer

;

Ashley G. Winter

;

Jonathan A. Coleman

;

11.5 Irreversible Electroporation (IRE) Prostate Ablation

;

Ashley G. Winter

;

Jonathan A. Coleman

;

12.1 Quality of Life With Surgery

;

Alana M. Murphy

;

Patrick J. Shenot

;

12.2 Quality of Life With Androgen Deprivation Therapy

;

Alana M. Murphy

;

Patrick J. Shenot

;

12.3 Quality of Life With External Beam Radiation Therapy

;

Steve K. Williams

;

Sameer Chopra

;

Farhang Rabbani

;

12.4 Quality of Life With Brachytherapy for Low-Risk Localized Prostate Cancer

;

Steve K. Williams

;

Farhang Rabbani

;

13 Role for Comparative Effectiveness Research in Treatment Decision Making

;

Ryan T. Jones

;

Mark V. Mishra

;

Timothy N. Showalter

;

14 Defining Treatment Failure for Localized Prostate Cancer: PSA and Beyond

;

Nicholas G. Zaorsky

;

Robert B. Den

;

Jianqing Lin

;

15 Prognosis After Biochemical Failure and Surrogate Endpoints for Prostate CancerñSpecific Mortality

;

Peter Orio

;

Nathan Bittner

;

III.

;

Treatment for High-Risk, Localized, and Locally Advanced Disease

;

16 Treatment of High-Risk Prostate Cancer: The Role of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy

;

Thomas J. Pugh

;

IV.

;

Treatment of Disseminated Disease

;

17 Salvage Therapy for Rising PSA

;

Judd W. Moul

;

18 Metastatic Hormone Sensitive Prostate Cancer

;

Jean Hoffman-Censits

;

William Kevin Kelly

;

19.1 Metastatic Castrate-Resistant Prostate Cancer: Mechanisms of Hormone Escape

;

Susan F. Slovin

;

19.2 Metastatic Castrate-Resistant Prostate Cancer: Role of Chemotherapy and Multifaceted Treatment Paradigms

;

Abdel Hai Alqwasmi

;

Nicholas G. Zaorsky

;

Ulka Vaishampayan

;

19.3 Metastatic Castrate-Resistant Prostate Cancer: Role of Androgen Signaling Inhibitors

;

Austin Poole

;

Ajjai Alva

;

Julia Batten

;

Neeraj Agarwal

;

19.4.1 Radiation and the Immune System

;

Andrew Sharabi

;

Charles Drake

;

19.4.2 Immunotherapy: Agents Targeting Prostate Cancer

;

Gurveen Kaur

;

Naveed H. Akhtar

;

Beerinder K. Singh

;

Scott T. Tagawa

;

19.5 Treatment of Bony Metastases: Inhibitors of Bone Resorption

;

Clara Hwang

;

Elisabeth I. Heath

;

19.6 Treatment of Bone Metastases: Radiopharmaceuticals

;

Hossein Jadvar

;

Leslie Ballas

;

David I. Quinn

;

19.7 Prognostication of Metastatic Castration-Resistant Prostate Cancer

;

Alan D. Smith

;

Joaquin Mateo

;

Johann S. de Bono

;

Index

; ; "

Authors

Adam P. Dicker, MD, PhD, is Professor and Chairman, Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA.

William Kevin Kelly, DO, is Professor, Department of Medical Oncology and Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA.

Nicholas G. Zaorsky, MD, is at the Department of Radiation Oncology, Fox Chase Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.

Edouard J. Trabulsi, MD, is Associate Professor, Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA.

Charles R. Thomas, Jr., MD is Professor and Chairman of the Department of Radiation Medicine and Professor of Hematology/Oncology at the Oregon Health & Science University Cancer Institute.

Product Details